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Abstract 
Purpose: Exposure to high altitude has been shown to enhance both glucose and lipid utilization 
depending on experimental protocol. In addition, high and low blood glucose levels have been 
reported at high altitude. We hypothesized that gradual ascent to high altitude results in changes 
in glucose levels in healthy young adults.  
Methods: 25 adult volunteers, split into two teams, took part in the British Services Dhaulagiri 
Medical Research Expedition completing 14 days of trekking around the Dhaulagiri circuit in 
Nepal reaching a peak altitude of 5300m on Day 11 of the trek. Participants wore blinded 
continuous glucose monitors (CGM) throughout. Blood samples for c-peptide, pro-insulin and 
triacylglycerides were taken at sea level (UK) and in acclimatisation camps at 3600m, 4650m 
and 5120m. Energy intake was determined from food diaries.  
Results: There was no difference in time spent in hypoglycemia stratified by altitude. Nocturnal 
CGM readings (22.00-06.00 hrs) were chosen to reduce the short-term impact of physical 
activity and food intake and showed a significant (p<0.0001) increase at 3600m 
(5.53±0.22mmol/L), 4650m (4.77±0.30mmol/L) and 5120m (4.78±0.24mmol/L) compared to 
baseline altitude 1100m (vs  4.61±0.25mmol/L). Energy intake did not differ by altitude. Insulin 
resistance and B-cell function, calculated by homeostatic model assessment, was reduced at 
3600m compared to sea level.  
Conclusions: We observed a significant increase in nocturnal CGM glucose at 3600m and above 
despite gradual ascent from 1100m. Taken with the changes in insulin resistance and B-cell 
function, it is possible that the stress response to high altitude dominates exercise enhanced 
insulin sensitivity, resulting in relative hyperglycemia. 
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Introduction 1 
 2 
Ascent to high altitude (HA) is associated with significant risks but despite this mountaineering 3 
and HA trekking remain popular. As well as environmental factors, such as temperature and 4 
wind, low barometric pressure combined with physical activity induces physiological changes 5 
that can result in impaired exercise capacity, a spectrum of altitude-related illnesses and even 6 
death (1).  7 
 8 
To evaluate how harsh and inhospitable conditions affect people operating at HA the Defence 9 
Medical Services have conducted a wide-ranging programme of research investigating the 10 
effects of HA exposure (2-13). One area that remains relatively unexplored is how glucose 11 
homeostasis is affected by prolonged HA exposure.  Exercise-induced hypoglcemia in non-12 
diabetic subjects is recognised (14).  At altitude even mild neuroglycopenia could have serious 13 
repercussions for example, loss of concentration or delayed recognition of imminent danger, and 14 
may exacerbate the effects of acute mountain sickness (AMS). A greater understanding of 15 
glucose flux at altitude may allow appropriate prevention and management of both hypo- and 16 
hyperglcemia, especially in conjunction with other life-threatening conditions such as high 17 
altitude pulmonary oedema and high altitude cerebral oedema. 18 
 19 
Glucose is the most efficient fuel that the body can utilise, consuming less oxygen per unit of 20 
energy produced than either fat or protein (15). This is of relevance in hypoxic situations, such as 21 
those at HA. Sudden exposure to HA (4300m) has been shown to lower blood glucose levels in 22 
the first 40 hours (16). It has previously been postulated that hypoxaemia may enhance 23 
utilization of glucose by mechanisms that are yet to be fully elucidated (17-19) and reduce 24 
  
reliance on fat as a substrate (20). However, we have recently shown that acute exposure to HA 25 
reduces carbohydrate oxidation and increases fat oxidation during walking (21) and prolonged 26 
cycling exercise (22). These contrasting results may be due to differences in energy consumption 27 
because the degree to which blood glucose increases on rapid ascent to 4300m is higher if energy 28 
intake is adequate (23).   29 
 30 
Loss of appetite is a near universal consequence of rapid ascent to HA and has a significant 31 
effect on the ability to maintain energy balance and, theoretically, glycaemia. Anorexia may be 32 
mediated by hypothalamic mechanisms but gastrointestinal signals causing nausea as part of the 33 
syndrome of AMS are a common exacerbating factor. It has been reported that soldiers 34 
participating in field exercises in mountainous terrain have consistently high rates of daily 35 
energy expenditure, but limited dietary energy intake (24). Increased energy requirements, 36 
reduced food intake and factors driving muscle glucose uptake may therefore cause hypoglcemia 37 
which has the potential to adversely affect performance at HA and even exacerbate AMS. 38 
 39 
We hypothesised that ascent to HA results in a reduction in glucose levels and prolonged periods 40 
of hypoglcemia in healthy young adults. To investigate this, we undertook a novel observational 41 
study utilizing continuous glucose monitoring (CGM) in volunteers undertaking a high-altitude 42 
expedition to the Himalayas in 2016.   43 
  
Methods  44 
 45 
Subjects 46 
Participants (n=25) were recruited from those taking part in the British Services Dhaulagiri 47 
Medical Research Expedition (BSDMRE) (25). The volunteers were divided between two teams 48 
(Team 1 and Team 2) and completed 14 days of trekking around the Dhaulagiri circuit in Nepal. 49 
Team 1 comprised 13 participants (10 male, 3 female) and Team 2 had 12 volunteers (11 male, 50 
one female). Team 1 departed 14 days before Team 2. Weather conditions and average 51 
temperatures were similar for both groups; at the time blood samples were collected (~08.00am), 52 
DPELHQWWHPSHUDWXUHVLQWKHUHVHDUFKWHQWVZHUHDQGí&DW 3600, 4650, and 5120 m 53 
respectively. Both teams ascended to a peak altitude of 5300m, with acclimatization days on 54 
Days 7 and 10. In addition, Team 1 had a further acclimatization day at 5120m (details of 55 
altitudes and locations are in Table 1) whereas Team 2 only stayed at this altitude for one night 56 
(due to several participants suffering with AMS who needed to descend on medical advice). 57 
Food (3 meals a day and afternoon tea) were provided by a support team of porters and chefs, 58 
accompanying each team separately. Thus, individuals within each team were offered the same 59 
type (and similar quantities) of food; but the food provision was not the same between each 60 
team. In general, the trekkers woke at 06.00; after breakfast trekking began at 08.00 and 61 
continued until ~15.00 (although this was variable depending on the distance and altitude 62 
covered). During the trek, regular breaks took place and lunch was taken at around noon. On 63 
arrival at the next camp, tea and biscuits were provided and little physical activity undertaken. 64 
Supper was served at 19.00 and most people retired to their tents by 21.00.   65 
 66 
  
This study was conducted according to the guidelines laid down in the Declaration of Helsinki 67 
and all procedures were approved by the Ethics Advisory Committee at Leeds Beckett 68 
University and the Ministry of Defence Research Ethics Committee (624/MODREC/14). All 69 
participants gave written informed consent.   70 
 71 
Study design 72 
All participants wore blinded continuous glucose monitors throughout (Dexcom G4, San Diego, 73 
CA). CGM monitors were placed on the triceps area (participants were given the choice of 74 
triceps or abdominal wall) and replaced every 7 days. One CGM receiver stopped working after 75 
5 days and no further data was collected from that participant (male, Team 1) and their results 76 
were excluded. Measurements of capillary blood glucose were also recorded twice each day 77 
using a Bayer Contour (Parsippany, NJ) glucometer utilizing glucose dehydrogenase testing 78 
strips.  79 
 80 
A priori, it was decided to focus on nocturnal (22.00pm-06.00am) glucose measurements as the 81 
main outcome measurement, to minimize the effects of food intake and physical activity on the 82 
glucose levels thus hopefully allowing clearer determination of the effects of altitude. CGM data 83 
were analyzed to identify the mean blood glucose (BG) during night-time at Dharbang (1110m) 84 
and on the night of arrival at each acclimatization camp (3600m, Italian Base Camp; 4650m, 85 
Dhaulagiri Base Camp; 5120m, Hidden Valley), and each night of trekking. The overnight 86 
glycemic variability (measured by standard deviation (SD) and coefficient of variation (CV)) 87 
was also assessed using EasyGV (Oxford, UK) software. Time spent in hypoglycemia (all 88 
readings) was determined at pre-specified altitudes (<2000m, 2000-3000m, 3000-4000m, and 89 
  
>4000m). Three definitions of hypoglycemia were used; <3.9mmol/L (which correlates with the 90 
release of counter-regulatory hormones), <3.3mmol/L (associated with the onset of 91 
neuroglycopenic and adrenergic symptoms) and <2.8mmol/L (the point at which cognitive 92 
dysfunction can occur) (26).  All participants were asked to complete a standardized food intake 93 
diary and daily energy intake was calculated using Nutritics dietary analysis software (v1.8 for 94 
Windows; Nutritics, Dublin). One day of food recording for one participant was excluded due to 95 
mis-recording and data was subsequently analyzed to include all remaining data (143 results) and 96 
also excluding days when participants had gastrointestinal illness affecting food intake (137 97 
results). 98 
 99 
Blood sampling and assays 100 
Venous blood samples were collected at sea-level (in the United Kingdom) and at all research 101 
camps with participants in a fasted state. To prevent any extraneous influences from postural 102 
changes, all blood samples were collected after the participant had been seated for at least 5 min. 103 
One 5 mL pre-cooled EDTA tube (Sarstedt, Leicester, UK) was used to obtain samples for the 104 
determination of c-peptide and pro-insulin to investigate beta cell function and insulin 105 
sensitivity. Immediately after filling, the tube was spun at 1500 x g for 10 minutes in a centrifuge 106 
(CompactStar CS4, VWR) and then immediately frozen at either -20°C in a freezer (for UK 107 
measurements) or within a dry shipper containing liquid nitrogen (at each fixed camp) before 108 
being transferred to -80°C and stored until analysis. C-peptide was measured on plasma samples 109 
using an automated chemiluminesent immunoassay (Abbott Architect, Illinois, United States) 110 
and pro-insulin using a manual solid-phase two-site enzyme immunoassay (Mercodia 111 
Diagnostics, Upsalla, Sweden). To further understand the changes in overnight glucose observed 112 
  
at different altitudes, we calculated insulin resistance and beta cell function using Homeostatic 113 
Model Assessment (HOMA, http://www.dtu.ox.ac.uk/homacalculator/). We did not collect 114 
fasting plasma glucose and therefore used the mean CGM glucose between 5am-6am on the day 115 
samples were taken. CGM glucose levels were used from the first morning of trekking (Day 1) 116 
for the sea-level HOMA calculations. Plasma triacylglycerol (TAG) concentration was 117 
determined spectrophotometrically using colorimetric analysis from a commercially available kit 118 
(Instrumentation Laboratory Company, Lexington, MA, USA).  119 
 120 
Statistics 121 
GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla California USA, 122 
www.graphpad.com) was used for statistical analysis and graph creation. Data were checked for 123 
normality using the Shapiro-Wilk test. For unpaired data, one-way ANOVA was used with post 124 
KRF'XQQHWW¶VPXOWLSOHFRPSDULVRQWHVWIRUSDUDPHWULFGDWDDQGWKH.UXVNDO-Wallis test with 125 
'XQQ¶VSRVWKRFDQDO\VLVIRUQRQ-parametric data. Non-parametric repeated measures data was 126 
DQDO\]HGXVLQJWKH)ULHGPDQWHVWZLWK'XQQ¶VSRVWKRFDQDlysis. To investigate differences 127 
between adjacent Trek and Rest days data were analyzed by 2-ZD\$129$ZLWK6LGDN¶V128 
multiple comparison test. Statistical significance was set at p<0.05.  129 
  130 
  
Results 131 
 132 
Demographics 133 
The mean age of the participants was 27.7 (range 18-41). Due to severe acute mountain sickness, 134 
meaning that CGM sensors could not be replaced, data was not available for 3 participants at 135 
Hidden Valley (5120m).  136 
 137 
Effects of altitude on hypoglycaemia 138 
There were no differences in percent time spent in hypoglycemia overnight (<3.9, <3.3 and <2.8 139 
mmol/L) when the trekkers were at altitudes of less than 2000m, between 2000-3000m and 140 
3000-4000m or at more than 4000m (Table 2). 141 
 142 
Effects of altitude on mean glucose levels and energy intake 143 
There was a significant increase in mean nocturnal CGM glucose at Italian Base Camp (3600m), 144 
Dhaulagiri Base Camp (4650m) and Hidden Valley Camp (5120m), compared to Dharbang 145 
(1110m) (5.53±0.22 vs 4.77±0.30 vs 4.78±0.24 vs 4.61±0.25 mmol/L respectively; p<0.0001) 146 
(Figure 1). The mean nocturnal CGM glucose climbed steadily from Dharbang (4.61±0.25 147 
mmol/) during the first week of the trek (Figure 2A) peaking on the second night at Italian Base 148 
Camp (5.64±0.25 mmol/L), then falling immediately to around 5 mmol/L for the last 4 days. 149 
These results were largely replicated in both teams (Figure 2B and 2C) despite them trekking at 150 
different times. The changes in CGM glucose were not obviously a reflection of the daily energy 151 
intake values. The mean daily energy intake immediately preceding the nocturnal glucose 152 
measurements did not differ between Dharbang and the three acclimatisation Camps (1968±360 153 
  
vs 2220±558 vs 2354±690 vs 2363±434 Kcal, p=0.39) even when CGM glucose was most 154 
elevated (at the Italian Base Camp, 3600m). Energy intake was lowest on the first two days of 155 
the trek when several participants were suffering from gastrointestinal illness (diarrhoea and 156 
vomiting) resulting in reduced appetite independent of altitude (Supplementary Figure 1A). 157 
When results the effects of gastrointestinal disease were excluded there were no changes in 158 
energy intake at any altitude (Supplementary Figure 1B).  159 
 160 
Comparison of glucose levels on trekking and non-trekking (rest) days 161 
There was a significantly higher mean nocturnal (22.00-06.00 hrs) CGM glucose at the Italian 162 
and Dhaulagiri Base Camps on rest days compared with the day before (when participants were 163 
trekking) but lower readings were recorded at Hidden Valley Camp on the rest day (Figure 3A).  164 
Similarly, the mean daytime (06.00-22.00 hrs) CGM glucose levels were higher after a rest day 165 
at 3600m (Italian Base Camp) and Hidden Valley Camp (5120m), but not at Dhaulagiri (Figure 166 
3B). Energy intake was not different between trekking and rest days at any altitude (Figure 3C). 167 
 168 
Effects of altitude on glycaemic variability 169 
Measures of glycaemic variability were also examined. Nocturnal standard deviation and mean 170 
amplitude of glycaemia of CGM readings were not different significantly between Dharbang 171 
(1110m), Italian Base Camp (3600m), Dhaulagiri Base Camp (4650m) and Hidden Valley 172 
(5120m), however there was a statistical difference in nocturnal percent coefficient of variation 173 
(%CV) (p=0.02 by Kruksal-Wallis test). The difference between the median calibration capillary 174 
blood glucose and the temporally nearest CGM glucose reading did not change with altitude (-175 
0.28mmol/L at <2000m; -0.42mmol/L at 2-3000m; -0.33mmol/L at 3-4000m; -0.31mmol/L at 4-176 
  
5000m; -0.25mmol/L at >5000m, p=0.79).   177 
 178 
Effects of altitude on beta cell function and insulin resistance 179 
There were significant reductions in C-peptide (p<0.05) and Pro-insulin (p<0.0001) levels 180 
between sea-level (UK) and Italian Base Camp (3600m) but no difference between sea-level and 181 
Dhaulagiri Base Camp or Hidden Valley (Figure 4A and 4B). Insulin resistance significantly 182 
differed with altitude (p=0.04) and Holm-6LGDN¶VPXOWLSOHFRPSDULVRQVVKRZHGDVLJQLILFDQW183 
(p<0.05) reduction in insulin resistance between sea-level and Italian Base Camp, Dhaulagiri 184 
Base Camp and Hidden Valley (Figure 4C). Beta-cell function was also significantly different 185 
ZLWKDOWLWXGHS DQG'XQQ¶VPXOWLSOHFRPSDULVRQVVKRZHGDVLJQLILFDQWSUHGXFWLRQ186 
in beta cell function between sea-level and Italian Base Camp (Figure 4D). The Pro-insulin:C-187 
peptide ratio was not significantly altered by changes in altitude (p=0.33) (Figure 4E). 188 
Triacylglycerol significantly increased with altitude (p<0.0006) (Figure 4F). 189 
 190 
  191 
  
Discussion 192 
 193 
This is the first study to report the effects of gradual ascent to very high altitude on glucose 194 
levels measured by CGM in healthy volunteers. The participants, split into two groups, made it 195 
possible to compare whether the changes observed were reproducible in an environment where 196 
undertaking a controlled trial is not feasible.  It is important to note that the ascent profile was 197 
carefully designed to minimise the risk of the participants developing AMS, thus the daily ascent 198 
was rarely more than 500m and the pace of walking set at that of the slowest team member. We 199 
believe that this means the observed results reflect changes of acclimatization, rather than sudden 200 
exposure to HA. 201 
 202 
The lack of differences in percentage time spent in hypoglcemia as the trekkers gained altitude is 203 
likely to reflect the gradual ascent profile and adaptation to HA. Strikingly however, nocturnal 204 
glucose was significantly elevated, by around 0.8mmol/L, at 3600m compared to Dharbang 205 
(1100m) and the higher camps (at 4650m and 5120m). This was replicated in both Team 1 and 206 
Team 2. We interpret the hyperglcemia and improved insulin sensitivity demonstrated at 3600m 207 
to reflect parallel streams of adaptive physiology related to altitude (i.e. hypobaric hypoxia) and 208 
physical activity. A possible explanation is that physical activity pathway improves peripheral 209 
insulin sensitivity but the stress response to hypoxia dominates, raising blood glucose at the same 210 
time.  211 
 212 
It has previously been shown (23) that acute (same day) ascent from sea level to 4300m increases 213 
blood glucose on Day 3 by 9.1%. Likewise, healthy volunteers exposed acutely to 3500m 214 
  
altitude significantly increased plasma glucose from 4.59 mmol/L at sea-level to 5.53 mmol/L 215 
(28). Interestingly, a study in which individuals were flown from Kathmandu (1300m) to 216 
Namche (3500m) then trekked to Everest Base Camp (5300m) over 9 days, showed no change in 217 
fasting glucose (or insulin sensitivity) until they had been at Base Camp for 6 weeks (29). It is 218 
noteworthy that all these studies differ from ours because of their sudden exposure to HA. A 219 
reduction in the partial pressure of inspired oxygen is known to induce a stress response which 220 
includes activation of the sympathetic nervous system and increased resting levels of 221 
normetanephrine at 3375m (30). Increased catecholamines and sympathetic tone are associated 222 
with reduced insulin sensitivity at altitude (23, 28, 31, 32) which would explain the observed 223 
hyperglycaemia however our results show increased insulin sensitivity after gradual ascent to 224 
altitude. Others have shown no change during gradual acclimatization up to 5000m (29) or 225 
increases in glucose utilization on acute exposure to 4300m due to apparent increases in insulin 226 
action (19). The reasons for these divergent results are likely to related to different study 227 
protocols, including rate of ascent and the complex mechanisms that underlie variations in 228 
glucose concentration at altitude which include changes in beta cell insulin secretion, hepatic 229 
glucose production and tissue glucose uptake. 230 
 231 
We further hypothesised that hypobaric hypoxia would result in beta cell stress resulting in an 232 
increase in the Pro-insulin:C-peptide ratio at altitude (33). We observed no change in the Pro-233 
insulin:C-peptide ratio with altitude, however the reduced C-peptide and Pro-insulin levels at 234 
Italian Base Camp may indicate beta cell stress and relative insulin deficiency. This provides a 235 
potential mechanism whereby reduced insulin secretion occurs in response to hypoxia. Increased 236 
insulin sensitivity, as seen at all altitudes above sea-level in our study, which may be related to 237 
  
exercise (and possibly altitude-induced) is, at least in part, due to upregulation of skeletal muscle 238 
GLUT4 receptor translocation. In adult rats exposed to 9% inspired oxygen for 30 days GLUT4 239 
protein increased by 15-20% compared to controls (34). Furthermore, in immature (aged 21 240 
days) and adult (aged 6 months) rats exposed to a simulated altitude of 4878m there was 241 
increased leg muscle GLUT4 and reduced insulin receptor density after 7 days but these changes 242 
disappeared by 28 days (35). These results could explain our observed increase in peripheral 243 
insulin sensitivity. Reduced insulin secretion also leads to increased hormone sensitive lipase 244 
activity with subsequent increased lipolysis and greater levels of circulating triglycerides, as we 245 
have shown and has been observed in response to simulated ascent to HA (36). 246 
 247 
These results do not fit into a neat paradigm and the cellular mechanisms driving these findings 248 
are not known; thus, our proposed explanation (represented in Supplementary Figure 2) is 249 
deliberately simplified to include the components that we measured.  It should be noted that this 250 
description does not account for changes in multiple factors including the distribution and 251 
number of GLUT1 receptors, alterations in hypoxia-inducible fDFWRUVHJ+,)ĮPRGXODWLRQ252 
of insulin receptor density, variations in rate-limiting enzymes such as glucokinase or glucose-6-253 
phosphate, or the response of other hormones such as growth hormone, glucagon and thyroxine 254 
to altitude exposure. Furthermore, we recognise that plasma levels of glucose and TAG do not 255 
reflect tissue uptake nor oxidation, thus reduced clearance, insulin resistance and increased 256 
lipolysis may be important. 257 
 258 
The absence of consistent changes in markers of GV imply that the increase in mean nocturnal 259 
glucose seen at Italian Base Camp (3600m) was not due to greater glucose flux. The overall CV 260 
  
at all altitudes are all considered to reflect low levels of GV which has previously been defined 261 
as CV of <36% (37).  262 
 263 
We suspected that increased food intake may play a role in the higher glucose readings seen on 264 
rest days, however the results do not bear this out ± there was no greater energy intake on rest 265 
days. Although food diaries are recognised to have limited reproducibility and accuracy (27), the 266 
energy intake in our study is within the levels expected for adults at altitude. The increased CGM 267 
glucose observed on some trekking days preceding rest days may reflect an exercise-mediated 268 
increase in insulin sensitivity and increases in non-insulin mediated glucose uptake occurring on 269 
trekking days, and reduced physical activity on rest days, however the lack of consistency in 270 
these findings warrant further investigation.  271 
 272 
There were notable limitations to this study. The volunteers were nearly all white European 273 
young adults with reasonable levels of cardiovascular fitness and therefore the results may not be 274 
applicable to other populations. There was no standardised measurement of blood glucose (e.g. a 275 
YSI glucose meter) thus the CGM calibration by fingerprick glucose meter may be subject to 276 
error (indeed this has been noted before) (38). In addition, only two calibration readings were 277 
taken each day (the minimum recommended). The altitude and cold temperatures may also have 278 
affected the CGM readings. Continuous glucose monitoring has been investigated in vitro in a 279 
hypobaric chamber using solutions containing 2.9, 4.9 and 11.3 mmol/L glucose; under 280 
conditions mimicking altitude of 2500m and 5500m, continuous readings were obtained however 281 
there was a significant difference in the CGM at the lower and higher glucose concentration 282 
compared to normobaric CGM (39,40). To mitigate against cold, the participants were 283 
  
encouraged to keep their CGM receivers inside their inner pockets. Reassuringly, the difference 284 
between CGM and calibration glucose measurements did not change significantly with 285 
increasing altitude indicating that the CGM readings were at least consistent with those obtained 286 
from the fingerprick glucometers. Our sample size was too small to detect gender-based 287 
differences in glucose homeostasis in particular whether the phase of menstrual cycle (greater 288 
insulin resistance typically occurs during the luteal phase) in female trekkers; this could be 289 
investigated in a larger group. Although this study lacks a control arm of people trekking under 290 
similar conditions at sea-level, one of the strengths is that it was done in two different teams and 291 
thus the observed changes are independent of the time of trekking and other factors that might 292 
have affected a single group of people. Nevertheless, these results provide an insight into the 293 
changes in glucose homeostasis that that occur as acclimatization to HA takes place. 294 
 295 
In summary, we have shown a significant increase in nocturnal CGM glucose at 3600m and 296 
above following gradual ascent from 1100m. Taken with reduced insulin resistance and evidence 297 
of B-cell dysfunction, it is possible that the stress response to high altitude leads to relative 298 
insulin deficiency and this effect is greater than exercise-induced increase in insulin sensitivity, 299 
resulting in relative hyperglycemia. Future studies could measure catecholamines, cortisol and 300 
other stress markers as well as undertaking muscle biopsies to look at GLUT expression.  301 
  
Acknowledgements 302 
We are grateful to all the volunteers who took part in the study.  303 
Dexcom provided the continuous glucose monitoring kit. They had no role in study design, data 304 
analysis or writing of this manuscript. This data has not been presented elsewhere.  305 
NEH conceived the study, collected data, analyzed data, wrote the manuscript. KD collected data 306 
and reviewed/edited manuscript. SM analyzed samples, contributed to discussion, 307 
reviewed/edited manuscript. NSO conceived the study, wrote the manuscript. CN collected data. 308 
AM conceived the study and reviewed/edited manuscript. JOH conceived the study and 309 
reviewed/edited manuscript. DW conceived the study, wrote the manuscript. 310 
 311 
Conflict of interest 312 
NEH is the guarantor of this work and, as such, had full access to all the data in the study and 313 
takes responsibility for the integrity of the data and the accuracy of the data analysis. The results 314 
of the present study do not constitute endorsement by ACSM. 315 
 316 
  317 
  
References 318 
 319 
1. P W Barry, A J Pollard Altitude illness. BMJ. 2003;326:915-919 320 
2. Mellor AJ, Woods DR, O'Hara J, Howley M, Watchorn J, Boos C. Rating of perceived 321 
exertion and acute mountain sickness during a high-altitude trek. Aviat Space Environ 322 
Med. 2014;85:1214-1216 323 
3. Mellor AJ, Boos CJ, Ball S et al. Copeptin and arginine vasopressin at high altitude: 324 
relationship to plasma osmolality and perceived exertion. Eur J Appl Physiol. 2015;115:91-325 
98 326 
4. Boos CJ, Holdsworth DA, Hall DP, Mellor A, O'Hara J, Woods DR. Comparison of two 327 
methods of assessing total body water at sea level and increasing high altitude. Clin 328 
Physiol Funct Imaging. 2014;34:478-484 329 
5. Mellor A, Boos C, Stacey M et al. Neutrophil gelatinase-associated lipocalin: its response 330 
to hypoxia and association with acute mountain sickness. Dis Markers. 2013;35:537-542 331 
6. Woods DR, Mellor A, Begley J et al. Brain natriuretic peptide and NT-proBNP levels 332 
reflect pulmonary artery systolic pressure in trekkers at high altitude. Physiol Res. 333 
2013;62:597-603 334 
7. Boos CJ, Holdsworth DA, Woods DR, Green K, Naylor J, Mellor A. Cardiac biomarkers 335 
and high altitude pulmonary edema. Int J Cardiol. 2013;167:e65-e66 336 
8. Boos CJ, Hodkinson P, Mellor A, Green NP, Woods DR. The effects of acute hypobaric 337 
hypoxia on arterial stiffness and endothelial function and its relationship to changes in 338 
pulmonary artery pressure and left ventricular diastolic function. High Alt Med Biol. 339 
2012;13:105-111 340 
  
9. Woods DR, Davison A, Stacey M et al. The cortisol response to hypobaric hypoxia at rest 341 
and post-exercise. Horm Metab Res. 2012;44:302-305 342 
10. Woods DR, Begley J, Stacey M et al. Severe acute mountain sickness, brain natriuretic 343 
peptide and NT-proBNP in humans. Acta Physiol (Oxf). 2012;205:349-355 344 
11. Energy at high altitude. Hill NE, Stacey MJ, Woods DR. J R Army Med Corps. 2011 345 
Mar;157(1):43-8 346 
12. Woods DR, Stacey M, Hill N, de Alwis N. Endocrine aspects of high altitude 347 
acclimatization and acute mountain sickness. J R Army Med Corps. 2011;157:33-37 348 
13. Woods DR, Allen S, Betts TR et al. High altitude arrhythmias. Cardiology 2008;111:239-349 
246 350 
14. Brun JF, Dumortier M, Fedou C, Mercier J. Exercise hypoglcemia in nondiabetic subjects. 351 
Diabetes Metab (Paris). 2001;27:92-106 352 
15. Schippers MP, Ramirez O, Arana M, Pinedo-Bernal P, McClelland GB. Increase in 353 
carbohydrate utilization in high-altitude Andean mice. Curr Biol. 2012;22:2350-2354 354 
16. Johnson HL, Consolazio CF, Burk RF, Daws TA. Glucose-14 C-UL metabolism in man 355 
after abrupt altitude exposure (4,300 m). Aerosp Med. 1974;45:849-854 356 
17. Brooks GA, Butterfield GE, Wolfe RR et al. Increased dependence on blood glucose after 357 
acclimatization to 4,300 m. J Appl Physiol. 1991;70:919-927 358 
18. Brooks 1992 GA, Wolfel EE, Groves BM, Bender PR, Butterfield GE, Cymerman A, 359 
Mazzeo RS, Sutton JR, Reeves JT. Muscle accounts for glucose dispersal but not blood 360 
lactate appearance during exercise after acclimatization to 4,300 m. J Appl Physiol. 361 
1992;72:2435-2445 362 
19. Roberts AC, Reeves JT, Butterfield GE, Mazzeo RS, Sutton JR, Wolfel EE, Brooks GA. 363 
  
Altitude and B-blockade augment glucose utilization during submaximal exercise. J Appl 364 
Physiol. 1996;80:605-615 365 
20. Roberts AC, Butterfield GE, Cymerman A, Reeves JT, Wolfel EE, Brooks GA. 366 
Acclimatization to 4,300-m altitude decreases reliance on fat as a substrate. J Appl Physiol. 367 
1996;81:1762-1771 368 
21. Matu J, Deighton K, Ispoglou T, Duckworth L. The effect of moderate versus severe 369 
simulated altitude on appetite, gut hormones, energy intake and substrate oxidation in men. 370 
Appetite. 2017;113:284-292 371 
22. O'Hara JP, Woods DR, Mellor A, Boos C, Gallagher L, Tsakirides C, Arjomandkhah NC, 372 
Holdsworth DA, Cooke CB, Morrison DJ, Preston T,King RF. A comparison of substrate 373 
oxidation during prolonged exercise in men at terrestrial altitude and normobaric normoxia 374 
following the coingestion of 13C glucose and 13C fructose. Physiol Rep. 2017;5:e13101 375 
23. Barnholt KE, Hoffman AR, Rock PB, Muza SR, Fulco CS, Braun B, Holloway L, Mazzeo 376 
RS, Cymerman A, Friedlander A. Endocrine responses to acute and chronic high-altitude 377 
exposure (4,300 meters): modulating effects of caloric restriction. Am J Physiol Endocrinol 378 
Metab. 2006;290:E1078-E1088 379 
24. Hoyt RW, Jones TE, Baker-Fulco CJ et al. Doubly labeled water measurement of human 380 
energy expenditure during exercise at high altitude. Am J Physiol. 1994;266:R966-R971 381 
25. Mellor A, Bakker-'\RV-+RZDUG0%RRV&&RRNH09LQFHQW(6FRWW32¶+DUD-3382 
Clarke S, Barlow M, Deighton K, Hill N, Newman C, Cruttenden R, Holdsworth D, Woods 383 
D. British Services Dhaulagiri Medical Research Expedition; A unique military/civilian 384 
research collaboration. J R Army Med Corps. 2017;163:371-375  385 
  
26. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/l 386 
(54 mg/dl) should be reported in clinical trials: A joint position statement of the American 387 
Diabetes Association and the European Association for the Study of Diabetes. Diabetes 388 
Care. 2017;40:165-157 389 
27. De Castro JM. Methodology, correlational analysis, and interpretation of diet diary records 390 
of the food and fluid intake of free-living humans. Appetite. 1994:23;179-192 391 
28. Sawhney RC, Malhotra AS, Singh T, RAI RM, Sinha KC. Insulin secretion at high altitude 392 
in man. Int J Biometeor. 1986;30:231-238 393 
29. Siervo M, Riley HL, Fernandez BO, Leckstrom CA, Martin DS, Mitchell K, Levett DZ, 394 
Montgomery HE, Mythen MG, Grocott MP, Feelisch M. Effects of prolonged exposure to 395 
hypobaric hypoxia on oxidative stress, inflammation and gluco-insular regulation: The not-396 
so-sweet price for good regulation. PLoS One. 2014;9;e94915 397 
30. Woods DR, O'Hara JP, Boos CJ, Hodkinson PD, Tsakirides C, Hill NE, et al. Markers of 398 
physiological stress during exercise under conditions of normoxia, normobaric hypoxia, 399 
hypobaric hypoxia, and genuine high altitude. Eur J Appl Physiol. 2017;117:893-900 400 
31. Braun B, Rock PB, Zamudio S, Wolfel GE, Mazzeo RS, Muza SR, Fulco CS, Moore LG, 401 
Butterfield GE. Women at altitude: short-term exposure to hypoxia and/or alpha(1)-402 
adrenergic blockade reduces insulin sensitivity. J Appl Physiol. 2001;91:623-631 403 
32. Larsen JJ, Hansen JM, Olsen NV, Galbo H, Dela F. The effect of altitude hypoxia on 404 
glucose homeostasis in men. J Physiol. 1997;504:241-249 405 
33. 6DWR<,QRXH0<RVKL]DZD7<DPDJDWD.0RGHUDWH+\SR[LD,QGXFHVȕ-Cell 406 
Dysfunction with HIF-1±Independent Gene Expression Changes. PLoS One. 407 
2014;9:e114868 408 
  
34. Xia Y, Warshaw JB, Haddad GG. Effect of chronic hypoxia on glucose transporters in 409 
heart and skeletal muscle of immature and adult rats. Am J Physiol. 1997;273:R1734-410 
R1741 411 
35. Dill RP, Chadan SG, Li C, Parkhouse WS. Aging and glucose transporter plasticity in 412 
response to hypobaric hypoxia. Mech Ageing Dev. 2001;122:533-545 413 
36. Young PM, Rose MS, Sutton JR, Green HJ, Cymerman A, Houston S. Operation Everest 414 
II: plasma lipid and hormonal responses during a simulated ascent of Mt. Everest. J Appl 415 
Physiol 1989;66:1430-1435  416 
37. Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N, Owens DR. 417 
Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. 418 
Diabetes Care. 2017;40:832-838  419 
38. Oberg D, Ostenson CG. Performance of glucose dehydrogenase-and glucose oxidase-based 420 
blood glucose meters at high altitude and low temperature. Diabetes Care. 2005;28:1261 421 
39. de Mol P, Krabbe HG, de Vries ST, et al. Accuracy of handheld blood glucose meters at 422 
high altitude. PLoS One. 2010;5:e1548 423 
40. Adolfsson P, Ornhagen H, Eriksson BM, Gautham R, Jendle J. In-vitro performance of the 424 
Enlite Sensor in various glucose concentrations during hypobaric and hyperbaric 425 
conditions. J Diabetes Sci Technol. 2012;6:1375-1382 426 
  427 
  
Figure Legends 428 
 429 
Figure 1. Nocturnal glucose levels at baseline and acclimatization camps. Continuous 430 
glucose monitoring data collected between 22.00pm and 06.00am (n=24 at 1110, 3600 and 431 
4650m and n=21 at 5120m). Data are expressed as median and range and were analyzed by 432 
Friedman repeated measures ANOVA and 'XQQ¶VPXOWLSOHFRPSDULVRQWHVWfor post-hoc testing. 433 
**** p<0.0001 vs 1100m 434 
  
 435 
Figure 2. Nocturnal glucose levels during the BSDMRE trek. Continuous glucose monitoring 436 
data collected between 22.00pm and 06.00am (n=24; n=21 at 5120m). Data are expressed as 437 
median and range and were analyzed by Friedman repeated measures ANOVA and 'XQQ¶V438 
multiple comparison test for post-hoc testing. (A) all participants, n=24; (B) Team 1, n=12; (C) 439 
Team 2, n=12. *** p<0.0001 vs 1100m 440 
 441 
  
 442 
Figure 3. Differences between (A) nocturnal (22.00-06.00 hrs) and (B) daytime (06.00-22.00 443 
hrs) CGM glucose, and (C) Energy Intake (EI) on Trekking and subsequent Rest days. Mean (± 444 
SD) glucose and EI on Trekking (Tr) days and the following Rest (Re) days at 3600 (n=24 445 
CGM, n=12 EI), 4650 (n=24 CGM, n=12 EI) and 5120m (n=12 CGM and EI, due to no rest day 446 
for Team 2) are shown. Data were analyzed by 2-ZD\$129$ZLWK6LGDN¶VPXOWLSOH447 
comparison test between adjacent Trek and Rest days; * p<0.05 and **** p<0.0001 vs Trekking 448 
 449 
 450 
 451 
  
 452 
 453 
Figure 4. Markers of beta cell secretory function and insulin resistance at baseline and 454 
acclimatization camp. Changes in (A) fasting C-peptide, (B) fasting Pro-insulin, (C) HOMA-455 
IR, (D) HOMA-B (E) pro-insulin:C-peptide and, (F) fasting plasma triglycerides (n=16-21 at 456 
1110m; 18-21 at 3600m and 4650m; and n=9-11 at 5120m). Data are expressed as median ± IQR 457 
(box) and range (whiskers) and analyzed by one-way ANOVA or Kruskal-Wallis test and post-458 
hoc with Holm-Sidak's or 'XQQ¶VPXOWLSOHFRPSDULVRQWHVW, respectively. * p<0.05 and *** 459 
p<0.0001 vs Sea level 460 
 461 
  
 462 
 463 
Supplementary Figure 1. Energy intake during the BSDMRE trek. Changes in (A) energy 464 
intake ± all results, (B) energy intake - excluding results when the participant had gastro-465 
intestinal disease (6 results out of a total of 144). Hatched boxes show rest days. Data are 466 
expressed as median ± IQR (box) and range (whiskers) and analyzed by one-way ANOVA with 467 
'XQQ¶VPXOWLSOHFRPSDULVRQWHVWQ IURP7HDPSDQGSYVP 468 
 469 
  
 470 
 471 
Supplementary Figure 2. Proposed pathways influencing glucose levels during 472 
acclimatization to high altitude. FFA ± free fatty acid; TGs ± triglycerides; GLUT4 ± glucose 473 
transporter 4. 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
  
 482 
Day Route Altitude (m) reached at end of day 
1 Beni to Dharbang 1110 
2 Dharbang to Naura 1440 
3 Naura to Bogara 1880 
4 Bogara to Dobhan 2500 
5 Dobhan to Sallaghiri 3100 
6 Sallaghiri to Italian Base Camp 3600 
7 Acclimatisation day 3600 
8 Italian Base Camp to Japanese Base Camp 4150 
9 Japanese Base Camp to Dhaulagiri Base 
Camp 
4650 
10 Acclimatisation day 4650 
11 Dhaulagiri Base Camp to Hidden Valley 5120 
12 Acclimatisation day* 5120 
13 Hidden Valley to Yak Kartha 4270 
14 Yak Kartha to Marpha 2500 
 483 
Table 1: Routes and altitude during the BSDMRE. * Team 2 did not have an acclimatization 484 
day at Hidden Valley (Day 12) due to a number of team members having Acute Mountain 485 
Sickness and needing to descend 486 
 487 
 488 
  
Altitude (m) Percent time spent in hypoglcemia between 22.00pm ± 06.00am (%) 
<3.9 mmol/L <3.3 mmol/L <2.8 mmol/L 
<2000 12.8 (10.6) 3.60 (4.10) 1.08 (2.35) 
2000-3000 11.2 (10.1) 2.06 (2.71) 0.35 (0.81) 
3000-4000 10.2 (12.1) 3.31 (5.75) 1.42 (3.69) 
>4000 15.2 (12.5) 4.15 (5.87) 1.35 (2.83) 
 489 
Table 2. Percent time spent in hypoglycemia at different altitudes. Data shown are mean 490 
(SD), n=24, no significant differences noted between altitudes. 491 
 492 
 493 
 494 
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